Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies

Aclaris Therapeutics

WAYNE, PAAclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., securing worldwide rights, excluding Greater China, to two promising antibody therapies. This strategic move aims to enhance Aclaris’ position in the immunology sector, complementing its existing portfolio with both small and large molecule drugs.

“This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with both small and large molecule drugs,” said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris. The agreement includes BSI-045B, a clinical-stage anti-TSLP monoclonal antibody, and BSI-502, a pre-clinical stage bispecific antibody targeting both TSLP and IL4R.

Dr. Walker highlighted the compelling data from BSI-045B’s Phase 2a trial for atopic dermatitis, noting its potential to become a best-in-class therapy. “Despite recent advances with anti-TSLP and anti-IL4R therapies, there remains substantial unmet need for more effective and convenient treatment options,” he added.

The agreement also enhances Aclaris’ financial flexibility, supported by proceeds from a newly announced private placement financing, which extends their cash runway into 2028. This financial stability is expected to bolster the company’s strategic growth initiatives.

In conjunction with the deal, Aclaris announced the expansion of its leadership team. Hugh Davis, Ph.D., joins as President and Chief Operating Officer, and Steven Knapp, PharmD, steps in as Executive Vice President, Head of Regulatory & Quality. Their extensive experience in biologics and regulatory affairs is anticipated to drive the development of Aclaris’ new pipeline.

Biosion’s CEO, Mingjiu Chen, Ph.D., praised the collaboration, noting that “BSI-045B and BSI-502 demonstrate the power of our discovery capabilities in generating potential first and best-in-class therapeutics.” This partnership, therefore, positions Aclaris to advance innovative therapies addressing significant gaps in current treatment options for immune-mediated disorders.

READ:  Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan

As Aclaris continues its evolution in the immunology field, the partnership with Biosion underscores its commitment to bringing forth new and effective treatment options for patients globally.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.